Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS 39216-4505, USA.
Int J Neuropsychopharmacol. 2010 Sep;13(8):1089-101. doi: 10.1017/S1461145710000301. Epub 2010 Apr 15.
Serotonin1A (5-HT(1A)) receptors are reported altered in the brain of subjects with major depressive disorder (MDD). Recent studies have identified transcriptional regulators of the 5-HT(1A) receptor and have documented gender-specific alterations in 5-HT(1A) transcription factor and 5-HT(1A) receptors in female MDD subjects. The 5' repressor element under dual repression binding protein-1 (Freud-1) is a calcium-regulated repressor that negatively regulates the 5-HT(1A) receptor gene. This study documented the cellular expression of Freud-1 in the human prefrontal cortex (PFC) and quantified Freud-1 protein in the PFC of MDD and control subjects as well as in the PFC of rhesus monkeys chronically treated with fluoxetine. Freud-1 immunoreactivity was present in neurons and glia and was co-localized with 5-HT(1A) receptors. Freud-1 protein level was significantly decreased in the PFC of male MDD subjects (37%, p=0.02) relative to gender-matched control subjects. Freud-1 protein was also reduced in the PFC of female MDD subjects (36%, p=0.18) but was not statistically significant. When the data was combined across genders and analysed by age, the decrease in Freud-1 protein level was greater in the younger MDD subjects (48%, p=0.01) relative to age-matched controls as opposed to older depressed subjects. Similarly, 5-HT(1A) receptor protein was significantly reduced in the PFC of the younger MDD subjects (48%, p=0.01) relative to age-matched controls. Adult male rhesus monkeys administered fluoxetine daily for 39 wk revealed no significant change in cortical Freud-1 or 5-HT(1A) receptor proteins compared to vehicle-treated control monkeys. Reduced protein expression of Freud-1 in MDD subjects may reflect dysregulation of this transcription factor, which may contribute to the altered regulation of 5-HT(1A) receptors observed in subjects with MDD. These data may also suggest that reductions in Freud-1 protein expression in the PFC may be associated with early onset of MDD.
5-羟色胺 1A(5-HT1A)受体在患有重度抑郁症(MDD)的患者大脑中发生改变。最近的研究已经确定了 5-HT1A 受体的转录调节剂,并记录了女性 MDD 患者中 5-HT1A 转录因子和 5-HT1A 受体的性别特异性改变。双抑制结合蛋白-1(弗洛伊德-1)下的 5' 抑制元件是一种钙调节抑制剂,可负调节 5-HT1A 受体基因。本研究记录了 Freud-1 在人前额叶皮层(PFC)中的细胞表达,并对 MDD 和对照受试者以及慢性接受氟西汀治疗的恒河猴的 PFC 中的 Freud-1 蛋白进行了定量。弗洛伊德-1 免疫反应性存在于神经元和神经胶质细胞中,并与 5-HT1A 受体共定位。与性别匹配的对照组相比,男性 MDD 患者的 PFC 中 Freud-1 蛋白水平显着降低(37%,p=0.02)。女性 MDD 患者的 PFC 中 Freud-1 蛋白水平也降低(36%,p=0.18),但无统计学意义。当按性别合并数据并按年龄进行分析时,与年龄匹配的对照组相比,年轻 MDD 患者的 Freud-1 蛋白水平下降更大(48%,p=0.01)。同样,年轻 MDD 患者的 PFC 中 5-HT1A 受体蛋白显着减少(48%,p=0.01)与年龄匹配的对照组相比。与接受载体治疗的对照组相比,接受氟西汀治疗 39 周的成年雄性恒河猴的皮质 Freud-1 或 5-HT1A 受体蛋白没有明显变化。MDD 患者 Freud-1 蛋白表达减少可能反映了这种转录因子的失调,这可能导致 MDD 患者中观察到的 5-HT1A 受体调节改变。这些数据还表明,PFC 中 Freud-1 蛋白表达的减少可能与 MDD 的早期发病有关。